Erasca, Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $44.1 million, or $(0.14) per share, compared to a $33.9 million loss in the prior year period. Research and development expenses increased to $35.9 million from $21.2 million, driven by clinical trial costs and personnel expenses. The company holds $384.3 million in cash and marketable securities as of June 30, 2026. Erasca also announced updated clinical data for its lead candidate ERAS-0015, showing a 57% unconfirmed overall response rate in second-line KRAS G12X pancreatic cancer, and highlighted the completion of an upsized public offering that raised approximately $632.5 million in July 2026 to strengthen its balance sheet. Erasca is a clinical-stage precision oncology company focused on discovering and developing therapies for RAS/MAPK pathway-driven cancers.
